bioRxiv preprint doi: https://doi.org/10.1101/2020.11.24.395939; this version posted November 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma Kylee H Maclachlan1, Even H Rustad1, Andriy Derkach2, Binbin Zheng-Lin1, Venkata Yellapantula1, Benjamin Diamond1, Malin Hultcrantz1, Bachisio Ziccheddu3, Eileen Boyle4, Patrick Blaney4, Niccolò Bolli5,6, Yanming Zhang7, Ahmet Dogan8, Alexander Lesokhin1, Gareth Morgan4, Ola Landgren9* and Francesco Maura1,10* 1. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy. 4. NYU Perlmutter Cancer Center, New York, NY, USA. 5. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. 6. Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 7 Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8 Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9. Sylvester Comprehensive Cancer Center, University of Miami. Miami, FL, USA. 10. Department of Medicine, Weill Cornell Medical College, New York, NY, USA. *Co-senior authors Keywords: Multiple myeloma, copy number signatures, APOBEC, prognosis, chromothripsis Corresponding author: Francesco Maura, MD, Myeloma Service, Department of Medicine Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065 T: +1 646.608.3934 | F: +1 646.277.7116
[email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.11.24.395939; this version posted November 24, 2020.